PainReform CEO Ilan Hadar Discusses Latest Developments Related To PRF-110 To Help Tackle The Opioid Epidemic
PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Had
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and Its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
PainReform Advances Non-Opioid Pain Relief Solution, PRF-110, in Phase III Trials to Combat Opioid Crisis | NASDAQ:PRFV
Express News | PainReform Announces Closing of $4 Million Public Offering
PainReform Ltd. Adjusts Warrant Terms
Express News | PainReform Shares Are Trading Lower After the Company Priced Its $4 Million Public Offering
PainReform Prices Its $4M Offering at $0.80 Apiece; Shares Fall
Express News | PainReform Prices Offering Of 5M Shares And Warrants At $0.80/Share And Accompanying Warrant
PainReform to Issue 5M Ordinary Shares, and Warrants to Purchase Up to 5M Shares, at 80 Cents>PRFX
PainReform to Issue 5M Ordinary Shares, and Warrants to Purchase Up to 5M Shares, at 80 Cents>PRFX
PainReform Will Use Proceeds To Advance Clinical Studies, General Corporate Purposes >PRFX
PainReform Will Use Proceeds To Advance Clinical Studies, General Corporate Purposes >PRFX
Express News | PainReform Ltd - Warrants to Purchase up to 5 Mln Ordinary Shares at a Combined Public Offering Price of $0.80 per Share
PainReform to Raise $4M Via Placing>PRFX
PainReform to Raise $4M Via Placing>PRFX
Express News | PainReform Announces Pricing of $4 Million Public Offering
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), PainReform (PRFX) and IN8bio (INAB)
Aptevo Therapeutics, TRACON Pharmaceuticals, Biosig Technologies Among Healthcare Movers
BSGM, WAVE and TCBP Among Pre-market Losers
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today's pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings
AEYE, GSIT and VVPR Among Mid-day Movers
PainReform's PRF-110 Sets New Pain Relief Benchmark
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions
PainReform Ltd (NASDAQ:PRFX) announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available
No Data